Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anti-Retroviral Agents | 14 | 2024 | 1794 | 2.220 |
Why?
|
HIV Infections | 42 | 2024 | 17564 | 2.020 |
Why?
|
HIV Seropositivity | 10 | 2013 | 963 | 1.810 |
Why?
|
Drug Resistance, Viral | 3 | 2019 | 869 | 1.180 |
Why?
|
Substance Abuse, Intravenous | 5 | 2024 | 530 | 1.160 |
Why?
|
CD4 Lymphocyte Count | 21 | 2024 | 2596 | 1.130 |
Why?
|
Hepatitis C | 5 | 2024 | 1594 | 1.110 |
Why?
|
Antiretroviral Therapy, Highly Active | 7 | 2021 | 1903 | 1.070 |
Why?
|
Hepatitis C, Chronic | 2 | 2022 | 1031 | 0.910 |
Why?
|
Alcoholism | 5 | 2024 | 1993 | 0.770 |
Why?
|
Anti-HIV Agents | 9 | 2024 | 4567 | 0.770 |
Why?
|
HIV-1 | 10 | 2019 | 6966 | 0.670 |
Why?
|
Tuberculosis | 4 | 2023 | 2030 | 0.600 |
Why?
|
AIDS-Related Opportunistic Infections | 3 | 2018 | 664 | 0.510 |
Why?
|
Opioid-Related Disorders | 8 | 2024 | 2188 | 0.500 |
Why?
|
Comparative Effectiveness Research | 2 | 2024 | 712 | 0.500 |
Why?
|
Developed Countries | 4 | 2015 | 451 | 0.470 |
Why?
|
Epidemiologic Methods | 1 | 2019 | 1337 | 0.470 |
Why?
|
Research Design | 3 | 2024 | 6217 | 0.360 |
Why?
|
Drug Users | 2 | 2023 | 134 | 0.350 |
Why?
|
Hepacivirus | 5 | 2024 | 1342 | 0.340 |
Why?
|
Europe | 9 | 2018 | 3439 | 0.340 |
Why?
|
Substance-Related Disorders | 2 | 2022 | 4453 | 0.310 |
Why?
|
Uganda | 6 | 2024 | 1350 | 0.310 |
Why?
|
Russia | 3 | 2024 | 386 | 0.300 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2022 | 2291 | 0.290 |
Why?
|
Homosexuality, Male | 3 | 2024 | 1345 | 0.280 |
Why?
|
Viral Load | 8 | 2024 | 3399 | 0.280 |
Why?
|
Veterans | 1 | 2021 | 2671 | 0.280 |
Why?
|
Sarcoma, Kaposi | 1 | 2010 | 374 | 0.280 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2023 | 10358 | 0.270 |
Why?
|
Policy | 2 | 2023 | 515 | 0.260 |
Why?
|
Steroids | 1 | 2011 | 937 | 0.260 |
Why?
|
HIV | 4 | 2021 | 1596 | 0.250 |
Why?
|
Arthritis, Rheumatoid | 2 | 2011 | 3763 | 0.240 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2014 | 4419 | 0.230 |
Why?
|
Cohort Studies | 18 | 2024 | 41797 | 0.230 |
Why?
|
Naltrexone | 2 | 2024 | 319 | 0.220 |
Why?
|
Analgesics, Opioid | 9 | 2023 | 3837 | 0.220 |
Why?
|
Narcotic Antagonists | 3 | 2024 | 590 | 0.220 |
Why?
|
Adult | 33 | 2024 | 223542 | 0.220 |
Why?
|
Data Collection | 2 | 2022 | 3329 | 0.220 |
Why?
|
Drug Therapy, Combination | 6 | 2019 | 6320 | 0.220 |
Why?
|
Male | 41 | 2024 | 364781 | 0.210 |
Why?
|
Isoniazid | 2 | 2023 | 288 | 0.210 |
Why?
|
Humans | 64 | 2024 | 768451 | 0.210 |
Why?
|
Opiate Substitution Treatment | 2 | 2024 | 446 | 0.200 |
Why?
|
HIV Integrase Inhibitors | 1 | 2023 | 165 | 0.190 |
Why?
|
Antiviral Agents | 3 | 2022 | 3063 | 0.190 |
Why?
|
Female | 37 | 2024 | 396943 | 0.190 |
Why?
|
Drug Administration Schedule | 5 | 2017 | 4861 | 0.180 |
Why?
|
Poisson Distribution | 2 | 2012 | 509 | 0.170 |
Why?
|
Anti-Inflammatory Agents | 1 | 2010 | 1816 | 0.170 |
Why?
|
Time Factors | 9 | 2019 | 40271 | 0.170 |
Why?
|
Middle Aged | 23 | 2024 | 223418 | 0.160 |
Why?
|
Residential Treatment | 1 | 2020 | 112 | 0.160 |
Why?
|
Yoga | 1 | 2022 | 281 | 0.150 |
Why?
|
Crime Victims | 1 | 2022 | 347 | 0.150 |
Why?
|
Latent Tuberculosis | 1 | 2021 | 224 | 0.150 |
Why?
|
Observation | 2 | 2017 | 311 | 0.150 |
Why?
|
Health Literacy | 1 | 2023 | 467 | 0.150 |
Why?
|
Toxoplasmosis | 1 | 2018 | 94 | 0.140 |
Why?
|
Meningitis, Cryptococcal | 1 | 2018 | 67 | 0.140 |
Why?
|
Models, Biological | 1 | 2013 | 9505 | 0.140 |
Why?
|
Treatment Outcome | 9 | 2023 | 65409 | 0.140 |
Why?
|
AIDS Dementia Complex | 1 | 2018 | 154 | 0.140 |
Why?
|
Zinc | 1 | 2021 | 677 | 0.140 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 1 | 2018 | 133 | 0.140 |
Why?
|
Proportional Hazards Models | 8 | 2020 | 12561 | 0.140 |
Why?
|
Endocarditis | 1 | 2020 | 355 | 0.130 |
Why?
|
Antitubercular Agents | 2 | 2022 | 1390 | 0.130 |
Why?
|
RNA, Viral | 3 | 2013 | 2865 | 0.130 |
Why?
|
Social Stigma | 1 | 2022 | 785 | 0.130 |
Why?
|
Severity of Illness Index | 1 | 2013 | 15965 | 0.130 |
Why?
|
Hepatitis B | 1 | 2021 | 707 | 0.130 |
Why?
|
Benzoxazines | 2 | 2018 | 321 | 0.120 |
Why?
|
Social Class | 1 | 2024 | 2000 | 0.120 |
Why?
|
Substance Withdrawal Syndrome | 1 | 2020 | 628 | 0.120 |
Why?
|
Virus Diseases | 1 | 2021 | 723 | 0.120 |
Why?
|
Motivation | 2 | 2023 | 2034 | 0.120 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 3253 | 0.120 |
Why?
|
Tuberculosis, Multidrug-Resistant | 1 | 2022 | 938 | 0.120 |
Why?
|
Models, Theoretical | 2 | 2017 | 3590 | 0.110 |
Why?
|
Cause of Death | 3 | 2020 | 3727 | 0.110 |
Why?
|
Reverse Transcriptase Inhibitors | 2 | 2018 | 622 | 0.110 |
Why?
|
Low Back Pain | 1 | 2022 | 989 | 0.110 |
Why?
|
Alcohol Drinking | 2 | 2023 | 4052 | 0.110 |
Why?
|
Inflammation | 2 | 2011 | 10865 | 0.110 |
Why?
|
Ethanol | 3 | 2024 | 1334 | 0.110 |
Why?
|
Mycobacterium tuberculosis | 2 | 2022 | 1931 | 0.110 |
Why?
|
Statistics as Topic | 1 | 2019 | 2362 | 0.100 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1089 | 0.100 |
Why?
|
RNA | 1 | 2022 | 2727 | 0.100 |
Why?
|
Survival Rate | 3 | 2019 | 12875 | 0.100 |
Why?
|
Incidence | 6 | 2024 | 21552 | 0.100 |
Why?
|
HIV Reverse Transcriptase | 1 | 2012 | 214 | 0.100 |
Why?
|
Education | 1 | 2014 | 536 | 0.100 |
Why?
|
Nevirapine | 1 | 2012 | 273 | 0.090 |
Why?
|
Prospective Studies | 9 | 2022 | 54914 | 0.090 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 2018 | 2203 | 0.090 |
Why?
|
Referral and Consultation | 1 | 2023 | 3629 | 0.090 |
Why?
|
Delayed Diagnosis | 1 | 2014 | 469 | 0.090 |
Why?
|
Naloxone | 2 | 2024 | 371 | 0.080 |
Why?
|
Africa South of the Sahara | 1 | 2012 | 750 | 0.080 |
Why?
|
Follow-Up Studies | 5 | 2016 | 39430 | 0.080 |
Why?
|
Seroepidemiologic Studies | 1 | 2010 | 406 | 0.080 |
Why?
|
United States | 8 | 2024 | 73121 | 0.080 |
Why?
|
Confidence Intervals | 2 | 2014 | 2932 | 0.080 |
Why?
|
Healthcare Disparities | 1 | 2024 | 3412 | 0.080 |
Why?
|
Australia | 1 | 2012 | 1264 | 0.080 |
Why?
|
Mass Screening | 2 | 2015 | 5455 | 0.080 |
Why?
|
Epidemics | 1 | 2014 | 517 | 0.080 |
Why?
|
Prescriptions | 1 | 2011 | 387 | 0.080 |
Why?
|
Regression Analysis | 1 | 2017 | 6353 | 0.070 |
Why?
|
Linear Models | 2 | 2022 | 5880 | 0.070 |
Why?
|
Risk Factors | 6 | 2022 | 74915 | 0.070 |
Why?
|
Treatment Failure | 1 | 2013 | 2656 | 0.070 |
Why?
|
Canada | 1 | 2012 | 2143 | 0.070 |
Why?
|
Kidney | 1 | 2022 | 7064 | 0.070 |
Why?
|
Early Diagnosis | 1 | 2011 | 1196 | 0.070 |
Why?
|
Databases, Factual | 2 | 2012 | 8081 | 0.060 |
Why?
|
Young Adult | 6 | 2024 | 60045 | 0.060 |
Why?
|
Hepatitis C Antibodies | 1 | 2024 | 151 | 0.060 |
Why?
|
Alkynes | 2 | 2018 | 327 | 0.060 |
Why?
|
Buprenorphine | 2 | 2024 | 661 | 0.060 |
Why?
|
Cyclopropanes | 2 | 2018 | 437 | 0.060 |
Why?
|
Genotype | 1 | 2018 | 13047 | 0.050 |
Why?
|
Disease-Free Survival | 1 | 2013 | 6856 | 0.050 |
Why?
|
Needle-Exchange Programs | 1 | 2023 | 27 | 0.050 |
Why?
|
Risk Assessment | 2 | 2018 | 24311 | 0.050 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2021 | 4636 | 0.050 |
Why?
|
Glucuronates | 1 | 2022 | 40 | 0.050 |
Why?
|
Sexual Behavior | 1 | 2011 | 2200 | 0.050 |
Why?
|
Risk | 1 | 2013 | 9642 | 0.050 |
Why?
|
Morphine Derivatives | 1 | 2021 | 43 | 0.050 |
Why?
|
Algorithms | 1 | 2022 | 14158 | 0.050 |
Why?
|
Integrases | 1 | 2023 | 520 | 0.050 |
Why?
|
Syringes | 1 | 2021 | 58 | 0.050 |
Why?
|
Emergency Service, Hospital | 1 | 2021 | 7956 | 0.050 |
Why?
|
Lamivudine | 1 | 2022 | 368 | 0.050 |
Why?
|
Selection Bias | 1 | 2022 | 360 | 0.050 |
Why?
|
Cross-Sectional Studies | 4 | 2024 | 26351 | 0.040 |
Why?
|
Atrial Fibrillation | 1 | 2019 | 5162 | 0.040 |
Why?
|
Patient Acceptance of Health Care | 1 | 2014 | 3237 | 0.040 |
Why?
|
Tuberculin Test | 1 | 2021 | 205 | 0.040 |
Why?
|
Delayed-Action Preparations | 1 | 2024 | 969 | 0.040 |
Why?
|
Sputum | 1 | 2022 | 511 | 0.040 |
Why?
|
North America | 1 | 2023 | 1292 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2014 | 4049 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 1 | 2010 | 6537 | 0.040 |
Why?
|
Adolescent | 6 | 2024 | 89168 | 0.040 |
Why?
|
Aged | 4 | 2022 | 171520 | 0.040 |
Why?
|
Research Personnel | 1 | 2023 | 591 | 0.040 |
Why?
|
Trust | 1 | 2023 | 532 | 0.040 |
Why?
|
Physical Therapy Modalities | 1 | 2022 | 533 | 0.040 |
Why?
|
Americas | 1 | 2018 | 110 | 0.040 |
Why?
|
Cardiovascular Diseases | 1 | 2023 | 15638 | 0.040 |
Why?
|
Methadone | 1 | 2020 | 322 | 0.040 |
Why?
|
Massachusetts | 2 | 2020 | 8908 | 0.040 |
Why?
|
Obesity | 1 | 2019 | 13065 | 0.030 |
Why?
|
Multivariate Analysis | 1 | 2010 | 12096 | 0.030 |
Why?
|
Netherlands | 1 | 2021 | 2274 | 0.030 |
Why?
|
Socioeconomic Factors | 2 | 2024 | 7863 | 0.030 |
Why?
|
Chronic Disease | 1 | 2011 | 9382 | 0.030 |
Why?
|
Causality | 1 | 2022 | 1255 | 0.030 |
Why?
|
HIV Protease Inhibitors | 1 | 2018 | 432 | 0.030 |
Why?
|
Infection Control | 1 | 2022 | 985 | 0.030 |
Why?
|
Logistic Models | 1 | 2010 | 13324 | 0.030 |
Why?
|
Paris | 1 | 2014 | 41 | 0.030 |
Why?
|
Benzodiazepines | 1 | 2021 | 1139 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2022 | 14766 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2011 | 7451 | 0.030 |
Why?
|
Consensus | 1 | 2023 | 3207 | 0.030 |
Why?
|
France | 1 | 2014 | 497 | 0.030 |
Why?
|
Retrospective Studies | 4 | 2023 | 81834 | 0.030 |
Why?
|
Point-of-Care Systems | 1 | 2022 | 1228 | 0.030 |
Why?
|
Pandemics | 2 | 2022 | 8753 | 0.030 |
Why?
|
Liver Cirrhosis | 1 | 2022 | 1950 | 0.020 |
Why?
|
Immune Reconstitution Inflammatory Syndrome | 1 | 2012 | 61 | 0.020 |
Why?
|
Neoplasms | 1 | 2021 | 22386 | 0.020 |
Why?
|
Pneumocystis carinii | 1 | 2012 | 72 | 0.020 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2012 | 242 | 0.020 |
Why?
|
Self Report | 1 | 2022 | 3771 | 0.020 |
Why?
|
Hospitals | 1 | 2022 | 3906 | 0.020 |
Why?
|
Health Personnel | 1 | 2022 | 3384 | 0.020 |
Why?
|
Computer Simulation | 1 | 2022 | 6278 | 0.020 |
Why?
|
Smoking | 1 | 2024 | 9099 | 0.020 |
Why?
|
Pain | 1 | 2022 | 5096 | 0.020 |
Why?
|
China | 1 | 2013 | 2398 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2024 | 5510 | 0.020 |
Why?
|
Mortality | 1 | 2017 | 2917 | 0.020 |
Why?
|
Disease Progression | 2 | 2014 | 13655 | 0.020 |
Why?
|
Health Promotion | 1 | 2017 | 2215 | 0.020 |
Why?
|
Cognition | 1 | 2022 | 7066 | 0.010 |
Why?
|
Medicare | 1 | 2022 | 6881 | 0.010 |
Why?
|
Body Mass Index | 1 | 2019 | 13030 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2019 | 22293 | 0.010 |
Why?
|
Hospitalization | 1 | 2020 | 10845 | 0.010 |
Why?
|
Concepts
(198)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(26)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_